Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Study of AZD9291 (Osimertinib) and BC2059 (Tegavivint) as First-Line Therapy in Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Next Previous
X
Search
Trial Profile

A Phase Ib Study of AZD9291 (Osimertinib) and BC2059 (Tegavivint) as First-Line Therapy in Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Osimertinib (Primary) ; Tegavivint (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 07 Dec 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2024.
    • 09 Dec 2021 According to Iterion Therapeutics media release, this study is sponsored by Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) and funded by Pelotonia.
    • 09 Dec 2021 Status changed from not yet recruiting to recruiting, according to Iterion Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top